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Purpose: To investigate the short-term effects of panretinal photocoagulation (PRP) combined with an intravitreal 
injection of Avastin
® (bevacizumab) as an adjuvant to high-risk proliferative diabetic retinopathy (PDR). 
Methods: The data was collected retrospectively from the eyes of high-risk PDR patients, which were divided into 
two groups. One eye was treated with only PRP (PRP only group) and the fellow eye of same patient was treated with 
both PRP and intravitreal bevacizumab injection (Adjuvant group). Best corrected visual acuity (BCVA), IOP (intraocular 
pressure), and new vessel (NV) size in fluorescein angiography were recorded immediately and at the six-week follow- 
up visit. Adverse events associated with intravitreal injection were investigated. 
Results: Of 12 patients with high-risk PDR, five were male and seven were female. There were no statistically significant 
BCVA or IOP changes after treatment in either group (p=0.916, 0.888). The reduction of NV size was found in both groups, 
but NV size in the adjuvant group showed a greater decrease than that of the PRP only group (p=0.038). Three patients 
had adverse events after intravitreal injection. Two patients had mild anterior uveitis and one patient had a serious 
complication of branched retinal artery obstruction (BRAO). 
Conclusions: Intravitreal bevacizumab injection with PRP resulted in marked regression of neovascularization compared 
with PRP alone. One serious side effect, BRAO, was noted in this study. Further studies are needed to determine 
the effect of repeated intravitreal bevacizumab injections and the proper number of bevacizumab injections as an 
adjuvant.  
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Retinal neovascularization represents an important risk 
factor for severe vision loss in patients with diabetic mellitus. 
Proliferative diabetic retinopathy (PDR) with high-risk cha-
racteristics has a worse prognosis than in normal diabetes 
patients. About 30% of patients have received additional 
laser treatment or surgery after initial panretinal photo-
coagulation (PRP).
1 
Until now, panretinal photocoagulation (PRP) has been 
one of the major treatments for PDR, as it reduces the like-
lihood of severe vision loss caused by various complications 
of diabetic retinopathy.
2 Immediate PRP is especially recom-
mended when high-risk factors are involved. However, this 
treatment causes various adverse effects, such as increased 
risk of macular edema, retinal atrophy, vitreous hemorrhage 
and decreased peripheral vision.
3,4 Furthermore, even after 
successful PRP, diabetic retinopathy progresses and surgical 
intervention may be required.
1,5
Vascular endothelial factor (VEGF) has been implicated in 
the neovascularization of the human eye and is an important 
factor for the progression of PDR. Ischemic retina due to 
microvascular occlusion induces the release of VEGF into 
the vitreous cavity; highly concentrated VEGF in the ocular 
fluid leads to the growth of a new vessel.
6 Also, VEGF 
increases the permeability of capillary vessels and contributes 
to diabetic macular edema.
7,8 Recently, drugs inhibiting 
VEGF (bevacizumab, Avastin
®;
 Genentech Inc., South San 
Francisco, CA, USA), one of the materials associated with 
vasculogenesis, have been developed and used. Bevacizumab 
(Avastin
®) was originally approved for treatment of 
metastatic colorectal cancer in the United States.
9 
There have been reports indicating the effectiveness of 
bevacizumab on rapid regression of new vessel (NV) after a 
single injection, but this effect does not seem to be long-term 
because NV tended to recur within 12 weeks.
10,11 The 
research herein investigated the effects of an intravitreal 
injection of Avastin
® as an adjuvant combined with PRP in 
high-risk PDR patients.YW Shin, et al. EFFECTS OF INTRAVITREAL BEVACIZUMAB INJECTION 
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Table 1. Clinical characteristics of the 12 patients enrolled in the current study
Case Injection
site
*
Sex Age
(yr)
DM
(yr)  
 
BCVA
(baseline)
BCVA
(follow-up)
IOP
(baseline) 
(mmHg)
IOP
(follow-up) 
(mmHg)
NV size
(baseline)
(pixels)
NV Size
(follow-up)
(pixels)
T
† C
‡ T CT C T C TC TC
1 OD M 55 15 0.2 0.1  0.1 0.0  17  15  15 20  12,535  9,435  3,893  7,592 
2 OD M 60 15 0.0 0.1  0.0 0.1  18  19  16 17  28,742  16,009  0  2,921 
3 OD F 51 4 0.3 0.3  0.4 0.4  20 20  17 16  27,716  35,487 19,059  32,915 
4 OD F 65 1 0.8 0.7  0.8 1.0  18 13  17 14  4,920  1,377  0  0 
5 OS F 51  1  0.2  0.2  0.2 0.1  16  17  15  12  4,134 2,842  1,587 1,890 
6 OS M 33 5 0.2 0.2  0.2 0.1  18 19  18 19  22,310  19,124 15,813  15,257 
7 OD F 47 15 0.7 0.1  0.2 0.0 19  18  15 18 7,896  4,443  - VH
8 OS F 53 10 1.0 1.0  1.0 0.8  14  13  17  16  16,147 3,548  4,653 VH
9 OS F 51 8 0.1 0.0 0.2 0.1 14 14 14 12 21,708 3,072 0 1,940
10 OS M 60 20 0.0 0.0 0.0 0.0 14 17 17 16 6,789 5,746 0 0
11 OS F 29 5 0.0 0.1 0.0 0.0 13 13 12 13 34,145 35,034 11,456 6,734
12 OD M 47 1 0.4 0.1 - - 16 15 - - 56,429 18,852 - -
Vitreous hemorrhage (VH) occurred in the control group in the eyes of cases 7 and 8. 
The case 8 patient experienced branched retinal artery obstruction. Case 12 was a follow-up loss. 
BCVA (logMAR)=best corrected visual acuity; IOP=intraocular pressure; NV=neovascularization; OD=right eye; OS=left eye.  
*The eye in which intravitreal Avastin® was injected; 
†Treatment group=Avastin® adjuvant therapy; 
‡Control group=panretinal photocoagulation
only therapy.
Materials and Methods
A retrospective, case-controlled study was performed in 
the department of ophthalmology, Hanyang University Guri 
Hospital. Medical records of 12 patients who were diagnosed 
with first-time high-risk PDR in both eyes and who were 
treated with PRP with an intravitreal injection of bevacizumab 
in one eye and single PRP therapy in the other eye were 
reviewed for this study. The patient data was collected from 
May 2007 to May 2008. None of the patients had ever re-
ceived any prior therapy before the first visit. We divided all 
study eyes into two groups. One group, defined as the control 
group, included eyes managed by single laser therapy. An-
other group, defined as the treatment group, consisted of eyes 
treated with laser therapy combined with a single adjuvant 
intravitreal bevacizumab injection. High-risk PDR was 
defined by Early Treatment Diabetic Retinopathy Study 
Research Group (ETDRS) guidelines.
12 Patients who had the 
following risk factors were assigned to the high-risk PDR 
group. 1) Presence of neovascularization of disc (NVD) > 
ETDRS standard photograph 10A; 2) less extensive NVD, if 
vitreous or pre-retinal hemorrhaging was present, 3) NV of 
elsewhere (NVE) ≥ 1/2 disc area, if vitreous or pre-retinal 
hemorrhaging was present. Exclusion criteria included 1) 
history of previous laser treatment, vitreoretinal surgery, or 
intravitreal injection; 2) history of another ocular disease 
other than PDR. Ophthalmologic evaluations were per-
formed, including anterior segment examination, logMAR 
best corrected visual acuity (BCVA), IOP measurement and 
fundus examination for baseline and follow-up data. Fundus 
photography and fluorescein angiography (FAG) were taken 
before the first PRP and at the six-week follow-up visit.
Study design
Data for 12 patients was reviewed. Both panretinal pho-
tocoagulation and intravitreal Avastin
® injection (treatment 
group) were performed for one eye, and only panretinal pho-
tocoagulation (PRP only group) was conducted on the fellow 
eye of same patient. Intravitreal Avastin
® injection was done 
after the first laser treatment using the following method: 1) 
the area around the eye was sterilized with 5% povidone 
/iodine, 2) intravitreal Avastin
® 0.05 mL (1.25 mg) was ad-
ministered using a tuberculin syringe with a 30 G needle, 3) 
antibiotic eye drops and oral antibiotics were prescribed for 
one week after the treatment. 
All injections were performed in the operating room. 
Patients visited an outpatient clinic for the examination of 
visual acuity, intraocular pressure, anterior segment, and fun-
dus the day after treatment. The panretinal photocoagulation 
protocol followed Diabetic Retinopathy Study Research 
Group guidelines. Before PRP, topical anesthesia using 0.5% 
proparacaine (Alcaine
®; Alcon Laboratories, Hunenberg, 
Switzerland) was dropped. Three hundred to four hundred 
argon laser (514 nm) burns with a spot size of 500 μm were 
made each time (800-1,600 burns in total) using a fundus 
contact lens (Transequator
®; Volk Optical, Mentor, OH, 
USA). Panretinal photocoagulation was executed in the 
inferior, nasal, superior, and temporal areas in both eyes, one 
each week over a two-week time period. 
Main outcomes
The differences in the two sets of eyes at 4-8 weeks after 
treatment were compared and analyzed using the fluorescein Korean J Ophthalmol Vol.23, No.4, 2009
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Table 2. Clinical characteristics of both groups in this study
Characteristics Adjuvant group PRP only group
Age (yr) 50.45±3.30
DM duration (yr) 9.00±1.95
logMAR BCVA (before treatment) 0.32±0.11 0.25±0.09
logMAR BCVA (after treatment) 0.28±0.10 0.24±0.11
IOP (before treatment) (mmHg) 16.45±0.72 16.18±0.81
IOP (after treatment) (mmHg) 15.73±0.52 15.73±0.82
NV size (before treatment) (pixels×10
3) 17.16±3.14 12.33±3.82
NV size (after treatment) (pixels×10
3 5.65±2.27 7.69±3.54 
Values are  mean±SD.
PRP=panretinal photocoagulation; DM=diabetes mellitus; BCVA=best corrected visual acuity; IOP=intraocular pressure; NV= 
neovascularization.
Table 3. Differences between baseline and follow-up visit in both groups
Group Mean difference p-value
*
BCVA (logMAR) Adjuvant 0.04±0.05 0.916
PRP only 0.02±0.04
IOP (mmHg, mean±SD) Adjuvant 0.73±0.66 0.888
PRP only 0.45±0.87
NV size (pixels × 10
3, mean±SD) Adjuvant 12.44±2.77 0.038
PRP only 6.48±3.00
BCVA=best corrected visual acuity;  PRP=panretinal photocoagulation; IOP=intraocular pressure; NV=neovascularization.
*Mean difference between adjuvant and PRP only group. Statistical significance was tested by Wilcoxon signed ranks test.
Fig. 1. New vessel (NV) size change at baseline and the follow-up 
visit. The NV regression of the treatment group is steeper than that of 
the control group. The result was statistically significant (p=0.038). 
C=control (panretinal photocoagulation only group); T=treatment 
(adjuvant group).
angiography image analysis program (Image J
®, Rasband, 
W.S. Image J ver. 1.36b; U.S. National Institutes of Health, 
Bethesda, MD, USA; http://rsb.info.nih.gov/ij/, 1977-2006). 
Also, BCVA, IOP, anterior segment results, and fundus status 
were compared. Adverse effects associated with intravitreal 
bevacizumab injection were evaluated, including BCVA 
(logMAR), size and activity of neovascularization on fundus 
angiography compared with baseline angiography, and 
intraocular pressure change. 
For image analysis, only the central views (50 degrees) of 
the angiographic images including NVDs were chosen in the 
mid-phase of FAG. Peripheral images were excluded 
because the size of same image was different by photograp- 
hing angle. In the presence of early NVD, it was difficult to 
outline the image, so another NVE prominent in the central 
view was selected. After choosing the images, the examiner 
outlined the area of NVD using the contrast enhancement 
tool Image J
®. The NV size was expressed in pixels. The 
Wilcoxon signed ranks test was used for statistical analysis 
with SPSS ver. 13.0 (SPSS Inc., Chicago, IL, USA). 
Results
Of the 12 patients with high-risk PDR, five were male and 
seven were female. The mean age was 50.45±3.30 years, and 
the mean diabetes duration was 9.00±1.95 years. All patients 
involved in this study had type 2 diabetes mellitus. Eleven 
patients remained to take a follow-up FAG examination six 
weeks after treatment (Tables 1 and 2) One patient was lost to 
follow-up. The baseline mean BCVA was 0.32±0.11 in the 
PRP only eyes and was 0.25±0.09 in the Avastin
® adjuvant 
eyes. After treatment, mean BCVA was 0.28±0.10 in the PRP 
only eyes and 0.24±0.11 in the Avastin
® adjuvant eyes 
(Tables 1 and 2). In both groups, there were no statistically 
significant BCVA changes after treatment (p=0.493, 0.705, 
respectively). No clinically significant macular edema was 
observed in any of the patients. Intraocular pressure was 
similar before and after treatment in both groups (p=0.574, 
0.310, respectively). Follow-up FAG examination showed YW Shin, et al. EFFECTS OF INTRAVITREAL BEVACIZUMAB INJECTION 
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Fig. 2. Case 3. A 51-yr-old female patient with bilateral high-risk proliferative diabetic retinopathy. (A, B) Actively leaking new vessels were 
observed in both eyes at baseline. She received the standard panretinal photocoagulation in both eyes. Intravireal bevacizumab injection was 
added to the treatment of her right eye. (C) At eight weeks, a marked decrease of leakage was noted in the right eye. (D) In her left eye, leakage 
from NV was slightly decreased but still actively persistent.
the reductions in NV size in both groups to be statistically 
significant (p=0.008, 0.005, respectively). The baseline area 
of NV was 12.33± 3.82 pixels (×10
3) in the PRP only group 
and 17.16±3.14 pixels (×10
3) in the Avastin
® adjuvant group. 
The follow-up NV results were 7.69±3.54 pixels (×10
3) in 
the PRP only group and 5.65±2.27 pixels (×10
3) in the 
Avastin
® adjuvant group (Table 3). Neovascularization size 
in the adjuvant group revealed more regression than did that 
of the PRP only group. (p=0.038) (Fig. 1). Clinically, based 
on FAG interpretation by a retinal specialist, all Avastin
® 
adjuvant eyes showed marked r e d u c t i o n  i n  N V  s i z e  a n d  
activity. In the PRP only group, NV size decreased but 
activity still remained in some patients (Fig. 2). 
Disease progression was found in two patients. Both pa-
tients had vitreous hemorrhages in the PRP only eye. The 
vitreous hemorrhages were not absorbed spontaneously, 
so vitrectomies were performed for both patients. Three 
patients had adverse events associated with intravitreal 
bevacizumab injection. Two had mild anterior uveitis that 
occurred one day after injection. These patients were 
prescribed antibiotic eye drops for seven days. No definite 
cell in the anterior chamber was found after one week in 
either patient. One patient suffered a branched retinal artery 
obstruction observed one month after the second injection 
(Fig. 3). This patient experienced amaurosis fugax-like 
symptoms in her left eye the day before the follow-up 
appointment. Her BCVA was decreased from 0.1 to 0.03. She 
received anticoagulant therapy after admission, but her Korean J Ophthalmol Vol.23, No.4, 2009
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Fig. 3. Case 1. A 53-yr-old female patient. (A) Neovascularization 
(NV) of the disc and a pre-retinal hemorrhage were seen at her first 
visit. Visual acuity in her left eye was 0.4. (B) After an intravitreal 
injection of bevacizumab, NV size decreased but persisted at six wk.
Therefore, a second injection was performed. She complained of sudden
visual loss and amaurosis at two wk after the second injection in her 
left eye. She visited our clinic 30 hr later with a visual acuity of 0.03. 
(C) A cherry red spot and retinal opacification were observed. 
Retinal arterial occlusion was diagnosed.
visual acuity in the involved eye was not recovered.
Discussion
Panretinal photocoagulation is a well-known principal 
therapy for proliferative diabetic retinopathy.
2 Although PRP 
reduces the possibility of severe visual loss, it has several 
side effects, such as macular edema, constricted visual field 
and laser-induced vitreous hemorrhage.
3,4 Also, additional 
laser therapy or surgical intervention has been necessary 
after PRP performance. Recent reports have shown that 
VEGF plays a key role in neovascularization of the eye, and 
that intravitreal anti-VEGF injection can lead to regression of 
NV in neovascular age-related macular degeneration, central 
retinal vein obstruction, iris neovascularization and pro-
liferative diabetic retinopathy.
6-8,10,11,13-15 Ehlers et al.
16 
discovered the combination intravitreal bevacizumab/PRP 
effect for treatment of neovascular glaucoma that rapidly 
decreases NV and IOP. 
Avery et al.
10 reported that rapid regressions in retinal and 
iris NV were shown after intravitreal bevacizumab injection. 
However, the recurrence of NV was noted in one patient. 
Another study by Jorge et al.
11 also showed the recurrence of 
NV leakage 12 weeks after injection. In this current study, we 
researched the difference in the regression and activity of NV 
between PRP with a single Avastin
® injection and with PRP 
alone in high-risk PDR patients. Marked regression of NV 
was observed in the Avastin
® adjuvant group compared with 
that of the PRP only group. Some eyes in the PRP only group 
developed new vitreous hemorrhages and vitrectomies were 
performed. It was thought that high-risk PDR patients were 
more vulnerable to destructive therapy like PRP that may 
induce vitreous hemorrhage. In this study, the effect of NV 
regression in the PRP only group had statistical significance 
(p=0.005). However, size and activity of the NV were more 
decreased in the Avastin
® adjuvant group, as confirmed with 
an FAG exam. The results were statistically significant (p= 
0.038). 
Tonello et al.
17 also showed that the adjuvant use of in-
travitreal bevacizumab injection with PRP induced greater YW Shin, et al. EFFECTS OF INTRAVITREAL BEVACIZUMAB INJECTION 
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NV regression than did PRP alone in high-risk PDR patients 
in short-term observation. Similarly, Mirshahi et al.
18 
evaluated the effect of bevacizumab-augmented retinal laser 
photocoagulation in high-risk PDR patients. They found that 
the combination therapy had a more effective response in the 
regression of NV at six weeks of follow-up. However, PDR 
recurred at week 16 of follow-up in the bevacizumab-injected 
eyes, and the complete regression rate was similar to that of 
the PRP alone group. We were unable to determine whether 
adjuvant therapy inhibits the recurrence of NV or maintains a 
long-term remission state.   Best corrected visual acuity was 
unchanged in both groups after treatment. These results were 
similar to those of other studies.
17 In our study, no significant 
macular edema was observed in either group during the study 
period. Macular edema is the leading cause of visual loss in 
diabetic retinopathy patients.
19 Because there was no 
development of clinically significant macular edema, it was 
thought that BCVA in the two groups was similar. However, 
when considering the possibility of PRP-induced macular 
edema, if a larger number of cases were included in the study, 
the BCVA of the Avastin
® adjuvant group might have been 
superior to that of the PRP only group because bevacizumab 
has been shown to reduce macular edema in diabetic reti-
nopathy.
20,21 Intraocular pressure changes were also not 
different between the two groups. Similar results were found 
in the literature.
11,17 Many reports showed that the injection 
of intravitreal bevacizumab was well-tolerated and safe. 
However, there was intraocular inflammation in two cases 
and one serious complication (branched retinal artery 
obstruction, BRAO) after intravitreal bevacizumab injection 
in this study. In the literature, some studies mentioned 
complications related to intravitreal bevacizumab injection. 
Bakri et al.
22 reported four occurrences of self-limited sterile 
uveitis after injection and our uveitis patients also had similar 
courses. Shima et al.
23 demonstrated various complications 
associated with intravitreal injection of bevacizumab in 
707 patients; not only intraocular complications but also 
extraocular complications, such as cerebral infarction, were 
shown. There were other studies highlighting arterial throm-
boembolic adverse events, including myocardial infarction 
and cerebrovascular accident, in the treatment of metastatic 
colon cancer with bevacizumab.
24,25 In our case, BRAO may 
have occurred due to the thromboembolic effects of beva-
cizumab. 
In conclusion, intravitreal bevacizumab injection with 
PRP resulted in marked regression of neovascularization and 
decreased the risk concerning newly developed vitreous he-
morrhage and rapidly progressing fibrovascular proliferation. 
Recently, many medical centers have begun to make attempts 
to apply intravitreal bevacizumab injections to various eye 
diseases, based on the successful results of previous studies. 
However, we experienced unfavorable adverse events 
after injection of bevacizumab. Therefore, intravitreal 
bevacizumab injection should be performed with caution 
until its long- term effects and safety are confirmed in future 
studies. A small sample size and short duration of follow-up 
were limitations of this study. Also, in the estimation of NV 
regression, it was difficult to outline the NV area in FAG cor-
rectly, and errors were possible with respect to the assessor’s 
subjectivity. Further studies are needed to determine the 
effects of repeated intravitreal bevacizumab injections and 
the proportions of adjuvant bevacizumab injection with PRP 
to reduce the risk of new vitreous hemorrhages and macular 
edema during treatment.
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